Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Neoplasms
Interventions: DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Capecitabine
Sponsor: Centre Leon Berard